Navigation Links
Amyloid Beta Level in Serum Predicts Risk for Vascular Disease in First-Degree Relatives of Alzheimer's Patients
Date:2/6/2009

People with a family history of Alzheimer’s disease, who have high levels of amyloid beta (A) in the serum, are at increased risk for vascular disease.

Manhasset, NY (Vocus) February 6, 2009 -- People with a family history of Alzheimer’s disease, who have high levels of amyloid beta (A²) in the serum, are at increased risk for vascular disease. These heightened A² levels may predict whether those without symptoms may progress towards dementia in years to come.

Michael Mullan, MD, and his colleagues at the Roskamp Institute in Sarasota, Fl., collaborated with statisticians at the London School of Hygiene and Tropical Medicine to see if elevated levels of A² in the blood in first-degree relatives of Alzheimer’s patients are associated with risk factors for vascular disease. Recent studies have shown that vascular disease is a major risk factor for Alzheimer’s. They recruited 197 local study subjects from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial, which included unaffected family members, as well as 98 community elders in Florida. They studied the association of amyloid beta levels in serum with risk factors for vascular disease, including total cholesterol, LDL, HDL, systolic blood pressure, diastolic blood pressure and serum creatinine. They also looked at medications prescribed for vascular disease or the risk factors associated with vascular disease.

A² in serum is used as a marker to predict A² accumulation in the brain, which is one of the key pathologies of Alzheimer’s. In this study, the scientists found A² levels were significantly higher in first-degree relatives of Alzheimer’s patients, as compared with the elder community controls. The scientists say they suspect this elevation may be “indicative of increased amyloid beta production due to genetic and/or other risk factors.”

“These findings suggest that an increased risk of Alzheimer’s disease associated with family history may be mediated in part through the enrichment of individuals with vascular risk factors and may be reflective of pre-symptomatic Alzheimer’s disease pathology,” Dr. Mullan and his colleagues wrote.

In another stunning finding in the same issue of Molecular Medicine, scientists from Virginia Commonwealth University, Northwestern University, UCSF, UCLA, University of Pennsylvania, and University of North Carolina, identified a genetic signature for a hepatitis C virus-induced liver cancer, and different genetic handprints for cirrhosis caused by hepatitis C. They were able to use these genetic signatures to distinguish between pathological stages of liver cancer and early disease states, suggesting a way to diagnose this hepatocellular carcinoma earlier in the disease process.

Molecular Medicine is published by The Feinstein Institute for Medical Research, part of the North Shore-LIJ Health System. For more information on the study, visit www.molmed.org or contact Veronica J. Davis. Free podcasts from the latest issue of Molecular Medicine are also available on the journal’s web site and in iTunes.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb1966994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
2. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
3. MSU study finds high level of medical mistrust among minority women impacts quality of health care
4. Ther-Rx Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
5. ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
6. New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level
7. Mammography utilization in the United States decreases: A state-level look
8. HPV18 DNA levels are not prognostic for precancerous cervical lesions
9. Cleveland Clinic and Mubadala Healthcare Name CEO of Cleveland Clinic Abu Dhabi
10. New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls
11. Children with inflammatory bowel disease have surprisingly high folate levels, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: